Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Algonquin Power & Utilities Corp. Fourth Quarter 2025 Earnings Call - Balance sheet repair and regulatory wins set stage for regulated growth, but higher tax rate trims 2027 EPS
Algonquin says 2025 was a turning point. Management used proceeds from strategic disposals to retire roughly $1.6 billion of debt, improved operating discipline, and secured a string of rate case sett...
- Company calls 2025 a turning point, saying it is transitioning to a premium pure-play regulated utility with a sharper leadership team and disciplined execution focus.
- Full-year results: GAAP net earnings of $208 million in 2025 versus $54.8 million in 2024; full-year Adjusted net earnings $258.8 million, up about 17% year over year.
- Per-share metrics: management reported full-year net earnings per share of $0.27 and Adjusted Net EPS of $0.34, beating prior guidance by $0.02; Q4 Adjusted Net EPS was $0.06, flat year over year.
- +12 more takeaways
Information Services Group Q4 2025 Earnings Call - AI Now ~30% of Revenue, Management Targets 50% with New AI Acceleration Unit
ISG closed 2025 with a clean, AI-flavored sprint. Q4 revenue came in at $61.2 million, up 6% year over year, and adjusted EBITDA jumped 24% to $8.1 million as margins expanded to 13.2%. Management sai...
- Q4 2025 revenue was $61.2 million, up 6% versus prior year, and at the high end of guidance.
- Q4 adjusted EBITDA rose 24% to $8.1 million, driving an EBITDA margin of 13.2%, roughly 189 basis points higher year over year.
- Full-year 2025 revenue was $245 million, up 7% year over year, and adjusted EBITDA exceeded $32 million, up 28% with full-year margin of 13.2%, up about 300 basis points.
- +12 more takeaways
Embraer Q4 2025 Earnings Call - Tariff Exemption Clears Path to Upside as Backlog Hits $31.6bn
Embraer closed 2025 with record revenue, a $31.6 billion backlog and momentum across commercial, executive, defense and services. Management beat financial expectations, delivered operational targets,...
- Record backlog: company-wide backlog reached $31.6 billion in Q4 2025, up about 20% year over year, with roughly $20 billion of customer options not included in backlog representing material upside.
- E2 momentum: commercial aviation booked 157 E2 new orders plus 140 options in 2025, lifting the commercial backlog to $14.5 billion and a 2.8-to-1 book-to-bill ratio for the division.
- Executive aviation peak quarter: Q4 revenues for executive aviation reached about $750 million, with 53 business jets delivered in the quarter, the highest quarterly tally ever.
- +14 more takeaways
Evaxion Full Year 2025 Earnings Call - Platform validated by MSD option and strong EVX-01 2-year data
Evaxion spent 2025 turning platform promise into tangible validation. The company secured an MSD option exercise on EVX-B3, won a Gates Foundation collaboration, and presented compelling EVX-01 phase ...
- MSD exercised its option for EVX-B3, marking an industry in-licensing validation of an infectious disease candidate discovered via Evaxion’s AI platform.
- MSD chose not to exercise its option on EVX-B2 (gonorrhea); Evaxion retained global rights and reports strong preclinical data and external interest.
- EVX-01 personalized neoantigen cancer vaccine reported 2-year phase 2 data: 75% objective response rate, 25% complete response rate, and 92% of responders remained in response at 24 months.
- +12 more takeaways
Genesco Fourth Quarter Fiscal 2026 Earnings Call - Journeys-led rebound masks Schuh reset, leaving FY27 sales flat while margins recover
Genesco closed fiscal 2026 with a clear story: Journeys is firing on all cylinders and carrying the quarter, but Schuh’s promotional reset and winding down of licenses will mute top-line growth in fis...
- Q4 revenue $800 million, up 7% year-over-year; comparable sales +9% (stores +9%, direct +8%).
- Journeys led Q4 with +12% comps, building on +14% in the prior-year quarter; Journeys outpaced the footwear market and grew total customers in December and January.
- Adjusted diluted EPS for Q4 was $3.74 versus $3.26 last year; full-year adjusted diluted EPS was $1.45 versus $0.94 the prior year.
- +12 more takeaways
Methanex Corporation Q4 2025 Earnings Call - Middle East supply shocks lift spot prices, company prioritizes debt paydown
Methanex closed 2025 with steady production, a $331/ton average realized price in Q4, and Adjusted EBITDA of $186 million, but an adjusted net loss of $11 million. Management is flagging a clear pivot...
- Q4 2025 headline metrics: average realized price $331/ton, produced sales ~2.4 million tons, Adjusted EBITDA $186 million, adjusted net loss $11 million.
- Q1 2026 realized price guidance estimated between $330 and $340 per ton, and management expects slightly higher Adjusted EBITDA in Q1 versus Q4.
- 2026 equity production guide is approximately 9 million tons, with regional rough breakdowns: North America a little over 6 million tons, Chile 1.3–1.4 million, Egypt 0.5–0.6 million, Trinidad ~0.8 million, New Zealand under 0.5 million.
- +12 more takeaways
Methode Electronics Q3 2026 Earnings Call - EBITDA Guidance Cut Amid Mexico Execution Issues, Offset by $120M Data Center Run Rate
Methode reported a soft quarter, squeezing profitability but still generating cash as it leans into industrial power and data center opportunities. Revenue was about $233.7 million, adjusted EBITDA wa...
- Q3 net sales were $233.7 million, a 3% decline year over year, reflecting softer North American automotive volumes and an interface segment program roll-off.
- Adjusted EBITDA for the quarter was $7.3 million, down about $5.0 million year over year; adjusted net loss was $13.1 million and adjusted loss per diluted share was $0.37.
- Management narrowed FY26 net sales guidance to $950 million to $1.0 billion, raising the low end largely due to a foreign exchange tailwind of approximately $30 million versus prior assumptions.
- +11 more takeaways
Granite Ridge Resources Q4 2025 Earnings Call - Pivot to Permian operator partnerships and a stated path to free cash flow in 2027
Granite Ridge reported another scaling year, with Q4 average daily production at 35.1k BOE per day and full-year average near 32k BOE per day, while adjusted EBITDAX landed at about $70 million in Q4 ...
- Company strategy pivoted from diversified non-operated investments to Permian-focused operated partnerships, led by Admiral Permian Resources, to capture high-return, short-cycle inventory.
- Q4 production averaged 35.1k BOE per day, full-year average ~31,984 BOE per day, representing ~27%-28% year-over-year growth; management expects 2026 average production of ~35,000 BOE per day (34k-36k guidance).
- Adjusted EBITDAX was approximately $69.5m in Q4 and $315m for full-year 2025; operating cash flow was $64.5m in Q4 and $296.4m for the year.
- +12 more takeaways
Kingstone Companies Fourth Quarter and Full Year 2025 Earnings Call - Record Profitability, Strong Underlying Metrics, 2026 Guided for CAT Normalization
Kingstone closed 2025 with its most profitable quarter and year in company history, driven by rapid premium growth, deeper retention of risk and a sharp improvement in underwriting performance. Q4 net...
- Q4 net income $14.8 million, diluted EPS $1.03, diluted operating EPS $1.08, GAAP net combined ratio 64.2, annualized ROE 51%.
- Full year 2025 net income $40.8 million, diluted EPS $2.88 (up 95%), return on equity 43%; most profitable year in company history.
- Direct premiums written: Q4 $82.8 million (up 14%); full year $277.8 million (up 15%); New York personal lines policies in force up over 7%.
- +15 more takeaways
Nutex Health Q4 2025 Earnings Call - CMS-driven IDR true-up crimps Q4 but core operations, cash flow, and IDR win rates show material improvement
Nutex Health reported a banner 2025 on a full-year basis, with revenue leaping 82% to $875.3 million and adjusted EBITDA surging to $259.6 million. The quarter looked ugly on headline comparisons afte...
- Full-year 2025 revenue grew 82% to $875.3 million from $479.9 million in 2024, driven by higher acuity claims and IDR recoveries.
- Adjusted EBITDA jumped 152.6% to $259.6 million for 2025, reflecting improved margins and arbitration-related revenue recognition adjustments.
- Net income was $70.8 million for 2025, which includes a one-time noncash stock-based compensation charge of $117 million tied to earnout shares for under-construction hospitals.
- +15 more takeaways